An observational study in Epithelial Ovarian Cancer, Peritoneal Cancer and Fallopian Tube Cancer, sponsored by ARCAGY/ GINECO GROUP. Completed at 137 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by ARCAGY/ GINECO GROUP · Observational
This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.
This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.
1,617 studies on the registry are indexed under Carcinoma, Ovarian Epithelial; 246 are open to participants now.
This study's enrollment of 1,500 is above the median of 150 across 304 observational studies indexed under Carcinoma, Ovarian Epithelial.
Browse Carcinoma, Ovarian Epithelial studies →ARCAGY/ GINECO GROUP is the lead sponsor of 51 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014)
Available tumor sample fixed in formalin and included in paraffin (FFPE):
Exclusion Criteria:
Correlation between Progression Free Survival (PFS) and the detected tumor genetic abnormalities
Time frame: From baseline until the date of progression or death, which ever occurs earlier, assessed up to 10 years
Correlation between age and the detected tumor genetic abnormalities
Time frame: Baseline
Correlation between histology status and the detected tumor genetic abnormalities
Time frame: Baseline
Correlation between FIGO stage and the detected tumor genetic abnormalities
Time frame: Baseline
Correlation between surgery resection status and the detected tumor genetic abnormalities
Time frame: Up to 10 years
Correlation between treatment response and the detected tumor genetic abnormalities
Time frame: Up to 10 years
Correlation between Overall survival (OS) and the detected tumor genetic abnormalities
Time frame: From baseline to death, assessed up to 10 years
Percentage of patients with both germinal and tumoral BRCA tests
Time frame: Up to 10 years
Percentage of patients with a first germinal BRCA test, a first tumoral BRCA test, or simultaneous germinal and tumoral tests
Time frame: Up to 10 years
Percentage of patients with and exploitable tumoral block for exploratory transversal researches
Time frame: Up to 10 years
Showing the first 100 of 137 sites.
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Ovarian Epithelial→
ARCAGY/ GINECO GROUP